BLFS
BioLife Solutions, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$35.25
−0.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 102.8M | 96.2M | 82.3M | 68.0M | 76.2M |
| Cost of Revenue | 36.5M | 34.1M | 28.6M | 26.7M | 29.3M |
| Gross Profit | 66.3M | 62.1M | 53.7M | 41.3M | 46.9M |
| Operating Expenses | |||||
| R&D Expense | 8.4M | 7.6M | 7.9M | 5.5M | 14.8M |
| SG&A Expense | 55.4M | 55.4M | 50.2M | 54.2M | 44.9M |
| General & Admin Expense | 45.5M | 45.5M | 40.5M | 42.8M | 33.3M |
| Selling & Marketing Expense | 9.8M | 9.8M | 9.6M | 11.4M | 11.7M |
| Other Expenses | (4.8M) | — | 2.7M | 1.0M | (6.9M) |
| Total Operating Expenses | 58.8M | 62.9M | 60.8M | 60.7M | 52.8M |
| Cost and Expenses | 95.4M | 97.3M | 89.4M | 87.4M | 82.2M |
| Operating Income (EBIT) | 7.5M | (1.1M) | (7.1M) | (19.4M) | (5.9M) |
| Non-Operating | |||||
| Interest Income | 2.0M | — | — | — | — |
| Interest Expense | 660.0K | 2.7M | 719.0K | — | 687.0K |
| Net Interest Income | 1.4M | (2.7M) | (719.0K) | — | (687.0K) |
| Other Non-Op Income/Expense | 612.0K | (11.0M) | (4.3M) | 7.2M | 1.1M |
| Non-Operating Income (excl Interest) | 1.2M | — | — | — | 4.8M |
| EBT (Pre-Tax Income) | 8.1M | (12.1M) | (11.4M) | (12.2M) | (4.8M) |
| Income Tax Expense | (42.4M) | 49.0K | (38.0K) | (64.0K) | (5.2M) |
| Bottom Line | |||||
| Net Income | 50.4M | (12.1M) | (20.2M) | (68.0M) | (139.8M) |
| Earnings from Cont. Ops | 50.4M | (12.1M) | (11.4M) | (12.2M) | 388.0K |
| Earnings from Discont. Ops | — | — | (8.8M) | (55.8M) | (140.2M) |
| Bottom Line Net Income | 50.4M | (12.1M) | (20.2M) | (68.0M) | (139.8M) |
| Per Share | |||||
| Basic EPS | $1.03 | ($0.25) | ($0.44) | ($1.55) | ($3.29) |
| Diluted EPS | $1.02 | ($0.25) | ($0.44) | ($1.55) | ($3.29) |
| Revenue Per Share | $2.10 | $2.01 | $1.79 | $1.56 | $1.79 |
| Shares | |||||
| Basic Shares Outstanding | 48.9M | 47.8M | 46.1M | 43.7M | 42.5M |
| Diluted Shares Outstanding | 49.3M | 48.6M | 46.1M | 43.7M | 42.5M |
| Profitability Metrics | |||||
| EBITDA | 9.8M | 3.6M | 1.5M | (7.1M) | (3.1M) |
| D&A | 3.6M | 4.7M | 8.7M | 12.3M | 7.6M |
| EBIT | 6.2M | (1.1M) | (7.1M) | (19.4M) | (10.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026